Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Journal of Cardiovascular Translational Research
Erschienen in:

07.12.2018 | Review

Advance for Cardiovascular Health in China

verfasst von: Yihua Bei, Chao Shi, Zhongrong Zhang, Junjie Xiao

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

As the most populous country worldwide, China has ≈ 290 million patients with cardiovascular diseases (CVDs), representing the leading cause of death in Chinese population. The morbidity and mortality of CVDs are continuously rising. Here, we will first summarize the recent advance in the management of CVDs such as coronary arterial disease, arrhythmia, and heart failure in China. In particular, we will introduce the development of chest pain centers and indicate the novel techniques and methods applied for the management of CVDs. Then, we will discuss and point out the importance of improving the clinical and basic research for Traditional Chinese medicine in the treatment of CVDs. Finally, we will emphasize the efforts made to promote cardiac rehabilitation and cardiovascular prevention system in China. We are striving to establish a practical prevention-treatment-rehabilitation system and looking forward to a bright future with reduced morbidity and mortality from CVDs in China.
Literatur
1.
Roth, G. A., Johnson, C., Abajobir, A., Abd-Allah, F., Abera, S. F., Abyu, G., et al. (2017). Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol, 70(1), 1–25.
2.
National Center for Cardiovascular Diseases, China (2018). Report on Cardiovascular Diseases in China 2017. Beijing: Encyclopedia of China Publishing House.
3.
Bei, Y., Yang, T., & Xiao, J. (2018). Cardiovascular medicine in China: what can we do to achieve the Healthy China 2030 plan? BMC Med, 16(1), 132.CrossRefPubMedPubMedCentral
4.
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation, 137(12), e67–e492.CrossRefPubMed
5.
Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association, Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians, Editorial Board of Chinese Journal of Cardiology. (2016). Chinese guideline for percutaneous coronary intervention (2016). Chin J Cardiol, 44(5), 382–400.
6.
Han, Y. L., & Rutherford, J. D. (2017). Recent evolution of the treatment of coronary artery disease in China: a conversation with Ya-Ling Han, MD, PhD. Circulation, 136(24), 2298–2302.CrossRefPubMed
7.
Tajti, P., Burke, M. N., Karmpaliotis, D., Alaswad, K., Werner, G. S., Azzalini, L., et al. (2018). Update in the percutaneous management of coronary chronic total occlusions. JACC. Cardiovascular Interventions, 11(7), 615–625.CrossRefPubMed
8.
Pu, J., Ding, S., Ge, H., Han, Y., Guo, J., Lin, R., et al. (2017). Efficacy and safety of a pharmaco-invasive strategy with half-dose alteplase versus primary angioplasty in ST-segment-elevation myocardial infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation, 136(16), 1462–1473.CrossRefPubMed
9.
Wu, H., Wang, Q., Zhou, J., Qian, J., & Ge, J. (2014). First report of stent thrombosis after a switch therapy resulting from ticagrelor-related dyspnea. International Journal of Cardiology, 176(3), e127–e128.CrossRefPubMed
10.
Qin, Q., Ma, J., Li, C., Ge, L., Qian, J., & Ge, J. (2015). Accidental extraction of a stent implanted 3 years earlier by a dislodged stent: a rare complication of percutaneous coronary intervention. JACC Cardiovasc Interv, 8(12), e197–e198.CrossRefPubMed
11.
Han, Y., Guo, J., Zheng, Y., Zang, H., Su, X., Wang, Y., et al. (2015). Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA, 313(13), 1336–1346.CrossRefPubMed
12.
Gao, R., Yang, Y., Han, Y., Huo, Y., Chen, J., Yu, B., et al. (2015). Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol, 66(21), 2298–2309.CrossRefPubMed
13.
Han, Y., Xu, B., Xu, K., Guan, C., Jing, Q., Zheng, Q., et al. (2016). Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circulation. Cardiovascular Interventions, 9(2), e003145.
14.
Wang, Z. Q., Qiang, H., Luo, X., Li, W., Guo, K., & Li, Y. G. (2018). Meta-analysis of risk of ventricular arrhythmias and all-cause mortality in patients with chronic total occlusion of a coronary artery and/or implantable cardioverter-defibrillator. The American Journal of Cardiology, 121(10), 1149–1154.CrossRefPubMed
15.
Cui, J., Du, X., Wu, J. H., Jia, C. Q., Li, X., Ning, M., et al. (2018). Effect of non-vitamin K antagonist oral anticoagulants on left atrial or atrial appendage thrombi in patients with nonvalvular atrial fibrillation. Zhonghua Xin Xue Guan Bing Za Zhi, 46(8), 606–610.PubMed
16.
Chen, Y., Zhang, Y., Huang, W., Huang, K., Xu, B., & Su, X. I. (2017). Primary and secondary stroke prevention using left atrial appendage closure with Watchman devices in atrial fibrillation patients: a single center experience from mainland China. Pacing and Clinical Electrophysiology, 40(6), 607–614.CrossRefPubMed
17.
Tang, X., Zhang, Z., Wang, F., Bai, Y., Xu, X., Huang, X., et al. (2017). Percutaneous left atrial appendage closure with LACBES((R)) occluder- a preclinical feasibility study. Circulation Journal, 82(1), 87–92.CrossRefPubMed
18.
Huang, H., Liu, Y., Xu, Y., Wang, Z., Li, Y., Cao, K., et al. (2017). Percutaneous left atrial appendage closure with the LAmbre device for stroke prevention in atrial fibrillation: a prospective, multicenter clinical study. JACC. Cardiovascular Interventions, 10(21), 2188–2194.CrossRefPubMed
19.
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology. (2018). Chinese guidelines for the diagnosis and treatment of heart failure 2018. Zhonghua Xin Xue Guan Bing Za Zhi, 46(10), 760–789.
20.
Jessup, M. (2014). Neprilysin inhibition--a novel therapy for heart failure. The New England Journal of Medicine, 371(11), 1062–1064.CrossRefPubMed
21.
Qin, S., Shi, H., Su, Y., Chen, S., Pan, W., & Ge, J. (2015). Can the prognosis of cardiac resynchronization therapy be predicted by gated SPECT? Clinical Nuclear Medicine, 40(10), 786–792.CrossRefPubMed
22.
Melman, Y. F., Shah, R., Danielson, K., Xiao, J., Simonson, B., Barth, A., et al. (2015). Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study. Circulation, 131(25), 2202–2216.CrossRefPubMedPubMedCentral
23.
Li, X., Zhang, J., Huang, J., Ma, A., Yang, J., Li, W., et al. (2013). A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. Journal of the American College of Cardiology, 62(12), 1065–1072.CrossRefPubMed
24.
Wang, Y., Han, X., Fu, M., Wang, J., Song, Y., Liu, Y., et al. (2018). Qiliqiangxin attenuates hypoxia-induced injury in primary rat cardiac microvascular endothelial cells via promoting HIF-1alpha-dependent glycolysis. Journal of Cellular and Molecular Medicine, 22(5), 2791–2803.CrossRefPubMedPubMedCentral
25.
Tao, L., Shen, S., Fu, S., Fang, H., Wang, X., Das, S., et al. (2015). Traditional Chinese medication qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice. Scientific Reports, 5, 8374.CrossRefPubMedPubMedCentral
26.
Spatz, E. S., Wang, Y., Beckman, A. L., Wu, X., Lu, Y., Du, X., et al. (2018). Traditional Chinese medicine for acute myocardial infarction in Western medicine hospitals in China. Circulation. Cardiovascular Quality and Outcomes, 11(3), e004190.CrossRefPubMedPubMedCentral
27.
Roh, H., & So, W. (2017). The effects of aerobic exercise training on oxidant–antioxidant balance, neurotrophic factor levels, and blood–brain barrier function in obese and non-obese men. Journal of Sport and Health Science, 6, 447–453.CrossRefPubMed
28.
Castro, E., Peinado, A., Benito, P., Galindo, M., González-Gross, M., & Cupeiro, R. (2017). What is the most effective exercise protocol to improve cardiovascular fitness in overweight and obese subjects? Journal of Sport and Health Science, 6, 454–461.CrossRefPubMed
29.
Salmoirago-Blotcher, E., Wayne, P. M., Dunsiger, S., Krol, J., Breault, C., Bock, B. C., et al. (2017). Tai Chi is a promising exercise option for patients with coronary heart disease declining cardiac rehabilitation. Journal of the American Heart Association, 6(10).
30.
Shi, J., Bei, Y., Kong, X., Liu, X., Lei, Z., Xu, T., et al. (2017). miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury. Theranostics, 7(3), 664–676.CrossRefPubMedPubMedCentral
31.
Liu, X., Xiao, J., Zhu, H., Wei, X., Platt, C., Damilano, F., et al. (2015). miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metabolism, 21(4), 584–595.CrossRefPubMedPubMedCentral
32.
Bei, Y., Xu, T., Lv, D., Yu, P., Xu, J., Che, L., et al. (2017). Exercise-induced circulating extracellular vesicles protect against cardiac ischemia-reperfusion injury. Basic Research in Cardiology, 112(4), 38.CrossRefPubMedPubMedCentral
33.
Wu, Y., Benjamin, E. J., & MacMahon, S. (2016). Prevention and control of cardiovascular disease in the rapidly changing economy of China. Circulation, 133(24), 2545–2560.CrossRefPubMedPubMedCentral
Metadaten
Titel
Advance for Cardiovascular Health in China
verfasst von
Yihua Bei
Chao Shi
Zhongrong Zhang
Junjie Xiao
Publikationsdatum
07.12.2018
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 3/2019
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-018-9852-7

Weitere Artikel der Ausgabe 3/2019

Interleukin-1 Receptor-Like 1 (IL1R1) Levels Are Not Increased in Healthy Centenarians

  • Correspondence

Identification of Radiofrequency Ablation Catheter Parameters That May Induce Intracardiac Steam Pops: Direct Visualization of Elicitation in Reanimated Swine Hearts

  • Original Article

Identification and Functional Characterization of an ISL1 Mutation Predisposing to Dilated Cardiomyopathy

  • Original Article

Autonomic Neuromodulation Acutely Ameliorates Left Ventricular Strain in Humans

  • Original Article

Comparative Quantification of Arterial Lipid by Intravascular Photoacoustic-Ultrasound Imaging and Near-Infrared Spectroscopy-Intravascular Ultrasound

  • Open Access
  • Original Article

lncRNA HOTAIR Protects Myocardial Infarction Rat by Sponging miR-519d-3p

  • Original Article

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Verschlechtert frühe Hyperoxie nach Reanimation die Prognose?

Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

LVAD auch bei kalt-trockener terminaler Herzinsuffizienz wirksam

Auch Personen mit kalt-trockener terminaler Herzinsuffizienz profitieren von einem linksventrikulären Unterstützungssystem (LVAD), wie Daten aus einem US-Register nahelegen. Doch es gibt Besonderheiten.     

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise